This might be attributed to the high levels of circulating TH17 cells and IL17 that have been reported in patients with melanoma prior to the initiation of immunotherapy and could be contributing to the increased risk of developing GSL [28,29]. This evidence concerns the gene IL17A and galactosialidosis.